Fungasol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fungasol

Quick Facts About Fungasol

Property Description
Active Ingredient (INN) Miconazole Nitrate
Pharmacological Class Azole Antifungal (Imidazole Derivative)
OTC Status Widely available Over-The-Counter (OTC)
Typical Forms Cream, Topical Solution, Powder, Vaginal Suppository
Primary Use Focus Superficial fungal and yeast skin infections

What is Fungasol and What is its Pharmacological Class?

Fungasol is the proprietary name for a medication containing the active compound Miconazole Nitrate, which is a widely available and clinically recognized antifungal agent. It belongs to the azole antifungal class of medicines, specifically designated as an imidazole derivative. This pharmacological classification is supported by the medicine’s long history of use and oversight, having been initially granted approval in the mid-1970s for topical use. This history demonstrates that the drug’s properties are well-established for decades of patient care.

Is Fungasol a Natural or Synthetic Compound, and What is its Composition?

As the active ingredient, Miconazole Nitrate is a synthetic pharmacological compound; it is not derived directly from a natural source, which ensures a consistent and stable pharmaceutical product. Its formulation is designed to disrupt the cell membranes of susceptible fungal pathogens. The final product includes this active ingredient in a specialized vehicle—such as a non-irritating cream base or a moisture-absorbing powder—which aids in effective delivery and is a differentiating characteristic depending on the specific product form.

What Ailments is Fungasol Generally Used For?

The overall therapeutic purpose of Fungasol is the initial management and treatment of superficial fungal and yeast infections, particularly those caused by Candida and dermatophytes. A typical use scenario involves fungal infections affecting the warm, moist areas of the body, such as tinea pedis (athlete's foot) or tinea cruris (jock itch). The broad-spectrum activity of Miconazole is clinically recognized for effectively eliminating these common pathogens and quickly resolving associated symptoms like itching and irritation.

What side effects are possible with Fungasol?

Possible Side Effects and Safety Information

The safety profile for Fungasol (Topical Miconazole Nitrate) is classified in official regulatory documents based on the type and frequency of reported events. The majority of adverse reactions are local effects confined to the application area, while the profile also includes rare, potentially serious systemic events, as defined by government health authorities.


Adverse Reaction Classifications

Side effects are categorized by frequency and the affected body system, primarily Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions.

  • Uncommon (1/1,000 to <1/100): Includes application site irritation, application site burning, application site pruritus (itching), skin burning sensation, skin inflammation, and skin hypopigmentation.
  • Not Known: Refers to reactions reported post-marketing where the frequency cannot be reliably estimated from available data. These include urticaria, contact dermatitis, rash, and erythema (redness).

Documented Safety Considerations

Serious Adverse Reactions have been documented, specifically severe hypersensitivity reactions such, as anaphylaxis and angioedema, which have been reported following the use of topical miconazole formulations.

Regarding specific patient groups, the regulatory label advises caution during pregnancy and lactation, noting that only small amounts of the active ingredient are absorbed following cutaneous application. Furthermore, the medication is formally contraindicated in individuals with known hypersensitivity to Miconazole Nitrate or to other medicines classified as imidazole derivatives.

In patients concurrently taking oral anticoagulants (e.g., warfarin), the official regulatory text specifies that although systemic absorption is minimal, caution should be exercised and the anticoagulant effect should be monitored.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information

Element Official Regulatory Statement
Documented overdose presentations Skin irritation (redness, swelling, burning sensation) from over-application.
Physiological systems affected (as stated in label) Local skin reactions. Systemic effects from ingestion are unspecified, but mandate urgent action.
Dose-related or exposure-related factors Accidental oral ingestion (swallowing) is the primary overdose exposure.
Population-specific overdose notes Mandate to keep out of reach of children to prevent ingestion.
Emergency-response statements Call a Poison Control Center (1-800-222-1222) right away if swallowed. Call 911 if collapsed or not breathing.
When immediate medical help is required If swallowed, get medical help immediately.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Life-threatening (if requiring 911 contact).
Regulatory basis FDA / DailyMed.
Overdose-context constraints Management is limited to appropriate supportive care for large ingestion.

Resulting Overdose Structure

Official overdose statements:

  • Accidental ingestion mandates immediate medical help or contacting Poison Control (1-800-222-1222) right away.
  • For life-threatening scenarios, such as the victim being collapsed or not breathing, contact local emergency services at 911.
  • Excessive topical use is associated only with local skin irritation symptoms; the regulatory label does not specify a known antidote.

Connection to the overall overdose profile (3 sentences):

Regulatory documents define the overdose profile by mandating immediate external medical intervention for the specific risk of accidental oral ingestion. This distinction clearly separates the systemic risk (requiring Poison Control) from the local effects of over-application, which are confined to skin irritation symptoms. The instructions strictly outline what action regulators require under these conditions.

Therapeutic Uses of Fungasol

What Fungasol Treats: Main Uses and Benefits

Fungasol is generally used to help manage symptomatic relief across therapeutic domains involving certain distressing symptoms, primarily those caused by common fungi and yeasts. In clinical practice, it is commonly used across conditions presenting with acute episodes, such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and cutaneous candidiasis. The medication is intended to assist with managing symptom clusters that may become intense or disruptive, such as noticeable itching, burning, and visible signs of irritation like scaling and cracking.

It is relevant when supportive symptom management is appropriate, often applied during phases when symptoms become more noticeable in warm, moist areas of the body like skin folds. The primary benefit sought is often the supportive management of acute discomfort, which may help patients cope more steadily with temporary functional strain. This action supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.


Quick Fact: Fungal Symptom Management

Fungasol contributes to improved comfort during symptomatic periods by managing the clustered symptoms of inflammation, itching, and burning associated with common superficial fungal infections. It is relevant for easing symptoms that interfere with daily comfort.

Regulatory References

  1. FDA-published DailyMed Label for Miconazole Nitrate

Eligibility and Restrictions for Use

Who can and cannot use Fungasol? — Official Regulatory Information

The eligibility for using Fungasol (Miconazole Nitrate) is strictly defined by government regulatory documents, focusing on absolute contraindications and specific population restrictions.

Eligibility Scope

Scope Item Official Regulatory Statement
Populations for whom use is allowed: Adults and Children 12 years of age and over are generally eligible for self-medication with OTC topical and vaginal forms.
Populations for whom use is contraindicated: Patients with known hypersensitivity (allergy) to Miconazole Nitrate or any other ingredient in the specific formulation.
Age-related eligibility rules: Children under 12 years of age must not use the medicine without consulting a healthcare professional. Use in infants less than 4 weeks of age is not recommended for some specialized products due to lack of demonstrated efficacy.
Condition-specific eligibility rules: Vaginal forms must not be used if the patient has never had a diagnosed yeast infection, or if they have specific systemic symptoms (e.g., fever, abdominal pain) indicating a more serious infection.
Pregnancy and lactation eligibility status: Pregnant or breast-feeding individuals are directed to consult a health professional before use for topical and vaginal forms.

Eligibility-Related Restrictions

Patients with frequent yeast infections, known diabetes, or a potentially weakened immune system are directed to consult a doctor before use. Additionally, patients taking warfarin must consult a doctor before using vaginal forms due to potential concurrent medication risk.

These official regulatory statements strictly define who is eligible, who is restricted, and who is contraindicated for use of Miconazole Nitrate.

What should I know about interactions with other medicines?

The official interaction profile is structured around the drug's capacity to inhibit key liver enzymes, primarily Cytochrome P450 (CYP) 3A4, and to a lesser extent, CYP2C9 and CYP2C19. This inhibition slows the clearance of co-administered medicines that are metabolized by these pathways, which can lead to significantly elevated plasma concentrations of the interacting drug.

Regulatory agencies define several Contraindicated Combinations (Do Not Use), classified as such because the resulting elevated drug levels carry a major risk of severe adverse events. These include antiarrhythmics like dofetilide and quinidine, certain sedatives like oral midazolam and alprazolam, and specific HMG-CoA reductase inhibitors (statins) such as simvastatin and lovastatin, due to the risks of QT prolongation, excessive sedation, and rhabdomyolysis, respectively.

Other significant interactions fall under the Use-With-Caution classification, requiring mandatory clinical monitoring and potential dose adjustment of the interacting medicine. This applies to oral anticoagulants (like warfarin) and immunosuppressants (like cyclosporine and tacrolimus), which necessitate frequent drug level or effect monitoring. Furthermore, official labels note that concomitant use with gastric acid suppressors (e.g., proton pump inhibitors, antacids) can reduce the antifungal's own absorption and efficacy, sometimes requiring the co-administration of an acidic beverage.

Mechanism of Action

Targeting Fungal Cell Membrane Synthesis

Fungasol acts within the domain of enzyme-mediated signaling in the fungal cell. The drug directly inhibits 14alpha-demethylase (a cytochrome P450 enzyme), which is critical in the fungal ergosterol synthesis pathway. This inhibition leads to the formation and accumulation of faulty, toxic cell membrane components and the depletion of functional ergosterol. This process initiates a cascade that causes disruption of fungal cell structure.


Modulating Microbial Structural Integrity

This mechanism modulates key pathways associated with microbial structural integrity. By blocking the production of ergosterol and promoting the accumulation of toxic intermediates, the drug alters membrane function and permeability. This core mechanism reduces the capacity for fungal cell proliferation; a resulting consequence is fungal cell death (lysis).

Dosage and Administration Information

How to Use Fungasol

Fungasol (Miconazole Nitrate) is administered via several routes, with the specific form and dosing regimen determined by the application site. The primary administration methods include cutaneous, intravaginal, buccal, and oral use, each with distinct instructions for the duration of the course and the required frequency.


Official Administration Guidelines

Usage Aspect Cutaneous Use (Topical) Intravaginal Use Buccal/Oral Use
Route of Administration Cream, powder, or ointment applied to the skin. Suppository or cream inserted intravaginally. Tablet or gel applied to the mouth/gum.
Standard Dosing A thin layer applied to the affected area. One 200 mg suppository daily for 3 days, or a single 1200 mg dose. One 50 mg buccal tablet daily or 2.5 mL oral gel four times daily.
Frequency & Duration Typically twice daily for up to 4 weeks (e.g., for athlete’s foot); continue for at least one week after symptoms resolve. Once daily at bedtime for multi-day courses, or as a single dose. Once daily for buccal tablet, or four times daily for oral gel, typically for 14 consecutive days.
Specific Timing Apply to cleaned and dried area, usually morning and evening. Administered at bedtime. Oral gel must be administered after meals.

Procedural and Age-Specific Rules

Proper use requires adherence to form-specific administration techniques. The Miconazole oral gel must be held in the mouth for two to three minutes before being swallowed, while the buccal tablet must be applied to the upper gum region and must not be crushed, chewed, or swallowed.

Age-specific administration rules exist primarily for pediatric patients. For example, Miconazole topical ointment is applied to the diaper area with each diaper change for up to seven days in infants four weeks and older. The oral gel is administered at a reduced dose (e.g., 1.25 mL four times daily) for specific younger age groups. If a buccal tablet is accidentally swallowed within the first six hours of application, a replacement tablet may be applied once.

Recent Clinical Evidence

The research available for Fungasol (Miconazole Nitrate) consists of clinical trials and scientific reviews that examine its use for common superficial fungal and yeast infections. The studies generally focus on defined patient groups and measure specific changes observed during short time periods. This overview summarizes the structure of the evidence base according to regulatory and scientific literature.


Evidence for Tinea Infections (Athlete's Foot, Ringworm, and Jock Itch)

Research into conditions characterized by episodic manifestations like Athlete's Foot and Ringworm has explored the compound through short-term Randomized Controlled Trials (RCTs). The primary outcomes studied have been mycological outcomes (lab confirmation of fungal pathogen eradication) and clinical outcomes (tracking observed changes in symptoms such as scaling and itching). Findings describe patterns of fungal eradication in trials comparing the active compound to an inactive vehicle. Long-term recurrence outcomes are not fully established, and comparative evidence is lacking against certain non-azole topical antifungals.


Evidence for Yeast Infections (Cutaneous Candidiasis)

Studies examined Cutaneous Candidiasis through short-term RCTs and comparative studies. The key outcomes studied include mycological outcomes (yeast eradication) and clinical outcomes (observing visible skin signs). Research provides insight into short-term changes observed in settings with varying symptom burdens. Data are still emerging regarding long-term patterns of potential antifungal resistance, and follow-up durations were often limited in standard efficacy studies.


Long-Term Studies and Durability of Response

Studies that have evaluated Fungasol have typically utilized short-term follow-up durations. The efficacy phase of most trials lasted for 2 to 4 weeks, with assessment of the sustained post-treatment status often tracked up to 6 weeks. The available evidence does not fully establish long-term effects related to outcomes measured beyond this limited observation window.


Evidence in Special Populations

Specific studies have examined the compound's use in neonates and infants, particularly in research contexts involving Cutaneous Candidiasis complicating conditions like diaper dermatitis. Most initial efficacy data involved the adult population. Data for groups such as the older adult population or those with significant comorbidities remain insufficient for detailed conclusions.


What Is Still Uncertain About Fungasol's Evidence

Scientific reviews note that the evidence quality varies across studies, and many early trials featured modest sample sizes. Comparative evidence against newer antifungal classes, particularly concerning long-term recurrence outcomes, is lacking. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions and group patterns under which they were conducted.

Key Studies & References

  1. Label: MICONAZOLE NITRATE 2% CREAM ANTIFUNGAL - DailyMed (NIH) - (Regulatory and Dosing Context)
  2. Miconazole Topical: MedlinePlus Drug Information (NIH) - (General Indication and Use Context)
  3. Consensus for the Treatment of Tinea Pedis: A Systematic Review of Randomised Controlled Trials - (RCT structure, mycological and clinical outcomes)
  4. What is the best treatment for oral thrush in healthy infants? - (Context on RCTs involving miconazole gel in infants for candidiasis)

Frequently Asked Questions (FAQ)

Common questions about Fungasol (FAQ)


Q: How quickly should I expect to see improvement after starting Fungasol?

A: Clinical data often suggests that some clinical improvement is observed within the first week of treatment with Fungasol. Complete resolution of the infection typically requires the full treatment course, which is often 2 to 4 weeks, depending on the type and site of the infection.

Q: Is it normal to feel a slight burning sensation when first applying Fungasol?

A: A skin burning sensation is documented in regulatory safety data as an uncommon side effect that occurs locally at the application site. If the burning is severe or accompanied by increased redness or swelling, consulting a healthcare professional is recommended.

Q: What topical products should not be used at the same time as Fungasol?

A: Official patient information for certain forms of Fungasol, such as vaginal suppositories, includes a warning that the medicinal base may potentially interact with latex products. General warnings for combining topical products are not broadly listed, but consulting a health professional before combining any treatments is generally advised.

Q: What happens if I accidentally miss an application of Fungasol?

A: Regulatory guidance for the oral buccal tablet form provides specific instructions regarding applying a replacement if the tablet is lost or swallowed outside of a specific time window. Specific instructions for accidentally missing a dose of topical cream or powder are generally not detailed on the official labels.

Q: What are the general safety guidelines for using Fungasol?

A: Regulatory documents advise several general precautions for use. Contact with the eyes should be avoided. It is also advised not to apply an airtight bandage or covering over the area unless specifically directed to do so by a healthcare professional. If severe irritation or an allergic reaction occurs, discontinuation is recommended.

Q: Is Fungasol the same as other common antifungal creams like Clotrimazole?

A: Fungasol contains Miconazole Nitrate, which belongs to the azole antifungal class. While many other common antifungal creams, such as Clotrimazole, also belong to this same pharmacological class (imidazole derivatives), they are distinct medications with different active ingredients.

Q: Does Fungasol cause skin dryness or peeling?

A: Official adverse reaction data lists local effects like dermatitis, rash, and redness. While dryness and peeling are not explicitly listed among the most common adverse reactions, skin irritation symptoms like dermatitis may sometimes involve related effects.

Q: What is the purpose of the different strengths of Fungasol available?

A: Fungasol is offered in different strengths and forms (e.g., creams, suppositories, oral gel). This is done so that the treatment can be matched to the severity and the specific site of the infection (such as the skin, mouth, or vagina) in accordance with official dosing schedules.

Q: Does Fungasol prevent the infection from spreading?

A: The drug's primary function is to destroy the existing fungus. Official patient advice, such as washing hands after application and avoiding sharing items, outlines practices that can help reduce the physical spread of infection.

Q: Are there any signs that a Fungasol side effect is serious?

A: Yes. Severe hypersensitivity reactions (severe allergies) have been reported in safety data. Signs that may suggest a serious reaction include swelling of the face, hands, or mouth, hives, or difficulty breathing or swallowing. Immediate medical attention is necessary if these occur.

Q: Is Fungasol okay to use during pregnancy (general query)?

A: Official labeling advises that individuals who are pregnant or breast-feeding should consult a health professional before use of the product. Only small amounts of the active ingredient are typically absorbed systemically from topical application, and this approach allows a health professional to determine the appropriate use.

Q: Does Fungasol have any systemic effects on the body?

A: Topical miconazole is minimally absorbed into the systemic circulation (the bloodstream). However, the oral and vaginal forms of Fungasol can result in slightly higher, yet small amounts of systemic absorption, which is why precautions related to drug interactions exist for those forms.

Q: Are there any foods or drinks I should avoid while using Fungasol?

A: Specific administration instructions for the oral forms include avoiding chewing gum when using the buccal tablet and administering the oral gel after meals. The regulatory information does not mandate general food or beverage restrictions for the topical product.

Q: Can Fungasol be used on the scalp or in hair?

A: Official product information indicates that Miconazole is used for fungal infections of the skin, which can include the scalp (Tinea capitis). Treatment of scalp infections may typically require a longer course compared to other skin infections.

Q: What should I do if the infection gets worse while using Fungasol?

A: Regulatory guidelines state that if symptoms do not improve, or if they appear to become worse, consulting with a doctor or healthcare provider is recommended. In such cases, a medical professional may need to confirm the diagnosis or adjust the course of treatment.

Q: Does Fungasol stain clothes or bedding?

A: Patient information leaflets often note that Miconazole creams are formulated to be non-greasy and are generally not expected to leave a stain on clothes or bedding.

Q: How long does the antifungal effect of Fungasol last after application?

A: Pharmacokinetic studies suggest that miconazole can remain detectable in the skin layers for up to four days after application. However, treatment instructions generally require application twice daily to maintain necessary therapeutic drug levels.

Q: Is it true that Fungasol works better if the area is kept dry?

A: Official patient advice for managing fungal skin infections, such as athlete's foot, often includes the general hygiene recommendation to keep the affected area clean and dry, as this general hygiene practice is advised to support the healing process.

Q: Can Fungasol be used for nail fungus (general curiosity)?

A: Official product information for Miconazole 2% cream indicates its use for fungal infections that affect the skin or nails. Treatment of nail fungus typically requires a significantly longer treatment duration than skin infections.

Q: Do I need to clean the application area in a special way before using Fungasol?

A: The official administration instructions require that the affected area must be cleaned and then thoroughly dried before the medication is applied. No specialized cleaning products or techniques are specified in the regulatory information.

Q: Why is Fungasol sometimes called a broad-spectrum antifungal?

A: Fungasol is often called a broad-spectrum antifungal because official regulatory overviews and clinical data recognize its effectiveness against a wide range of common fungal pathogens. This includes both the fungi that cause tinea (ringworm, athlete's foot) and various species of yeast (Candida).

Q: What is the maximum number of days Fungasol should generally be used?

A: The duration of treatment depends on the specific infection, but regulatory information often sets an initial treatment period of 2 to 4 weeks. If no improvement is observed after this time, a healthcare review of the diagnosis is typically recommended.

How should Fungasol be stored and disposed of?

How to Store and Dispose of Fungasol (Miconazole Nitrate)

Official regulatory guidelines ensure the stability and safe handling of Miconazole Nitrate topical products, often sold as Fungasol.


Storage Requirements

Item Official Regulatory Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), adhering to USP Controlled Room Temperature.
Handling Do not freeze and avoid excessive heat. Keep the tube or container tightly closed.
Safety The product must be stored out of the reach of children to prevent accidental ingestion or misuse.

Disposal Instructions

Discard any unused or expired product according to national guidelines, such as using a drug take-back program. If a take-back option is unavailable, the product may be mixed with an unappealing substance (like coffee grounds or dirt) and sealed in a bag before disposal in the household trash. The medication should not be flushed down the toilet or poured into any drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungasol found in:

A-Z Index: